Self-Replicating RNA Compositions for Sustained Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for infectious diseases and cancer are inadequate, with limited options for viral and eukaryotic infections and increasing antibiotic resistance, and cancer therapies are costly and often ineffective, necessitating a need for rapid vaccine development and improved therapeutic approaches.
Innovation Solution
Development of nucleic acid molecules comprising codon-optimized polynucleotides encoding viral replication proteins and antigenic proteins, which can be self-replicating RNAs for sustained protein expression, including alphavirus proteins and tumor antigens, to induce immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional polynucleotides encoding viral replication proteins are used, then the replication system can be established, but the protein expression level is insufficient and transient
Solution Approach 1:
The patent applies codon optimization to change the nucleotide sequence parameters of polynucleotides encoding viral replication proteins. By optimizing codon usage to match host cell preferences, the invention achieves enhanced translation efficiency and sustained protein expression without altering the amino acid sequence, thereby resolving the contradiction between expression level and duration
Solution Approach 2:
The invention creates self-replicating RNA systems that continuously produce viral replication proteins and antigenic proteins over extended periods. The self-replicating mechanism ensures continuous useful action by maintaining active replication cycles within host cells, transforming transient expression into sustained immune stimulation
2Loss of time
If rapid vaccine development is pursued to control emerging infectious diseases, then response time is reduced, but treatment effectiveness and immune response strength may be compromised
Solution Approach 1:
The patent employs pre-designed self-replicating RNA frameworks with codon-optimized viral replication protein genes that can rapidly express antigens upon introduction. This preliminary preparation of efficient expression systems allows rapid vaccine development against emerging diseases while maintaining strong immune responses through sustained antigen production
Solution Approach 2:
The self-replicating RNA system serves itself by using encoded viral replication proteins to continuously replicate the RNA and produce antigens within host cells. This self-service mechanism eliminates the need for repeated administrations or complex delivery systems, achieving both rapid deployment and sustained effectiveness
3Ease of manufacture
If traditional cancer therapies such as surgery and chemotherapy are used, then treatment options are available, but side effects are serious and life prolongation is modest
Solution Approach 1:
The patent uses self-replicating RNA as an intermediary to deliver tumor-associated antigen sequences into host cells. This RNA mediator triggers the immune system to recognize and attack cancer cells specifically, avoiding the non-specific toxicity of traditional chemotherapies while maintaining treatment availability through injectable formulations
Data Source
AI summary
Provided herein are nucleic acid molecules encoding viral replication proteins and antigenic proteins or fragments thereof. Also provided herein are compositions that include nucleic acid molecules encoding viral replication and antigenic proteins, and lipids. Nucleic acid molecules provided herein are useful for inducing immune responses.